1. What It Is (Mechanism of Action)
Melanotan II is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone ($alpha$-MSH). It acts as a potent non-selective agonist across melanocortin receptors MC1R, MC3R, MC4R, and MC5R.
2. Clinical Indications Under Study
Originally investigated for photoprotection and tanning; prompted subsequent research into the selective MC4R derivative bremelanotide (PT-141) for sexual dysfunction.
3. FDA Approval & Regulatory Status
Banned / Illegal for Human Use (FDA Blacklist & Warning Letters)
4. Human Clinical Evidence Summary
5. Known Risks, Side Effects & Boxed Warnings
Severe systemic risks: systemic hypertension, priapism, nausea, facial flushing, rapid darkening of atypical nevi (dysplastic moles), rhabdomyolysis, renal infarction, and potential acceleration of malignant melanoma. Subject to multiple FDA public health warnings and seizure actions.
6. Legal, Prescription & Compounding Status
Completely illegal to market, prescribe, or sell as a human drug in the United States, United Kingdom, Europe, and Australia.
7. Why Gray-Market "Research Chemical" Versions Are Risky
Get Breaking Melanotan II Clinical Trial Alerts
Receive verified FDA dockets, Phase 3 readouts, and independent HPLC lab audits directly from our medical journalism desk.
8. Questions to Ask a Licensed Clinician
If you are discussing this compound with your doctor or healthcare provider, consider bringing these evidence-based questions:
- Q1: What are the documented dermatological and oncogenic risks associated with non-selective melanocortin stimulation?
- Q2: How can I safely monitor preexisting moles and dysplastic nevi after exposure to unregulated tanning peptides?
9. Primary Peer-Reviewed Sources & Citations
- [1] FDA Consumer Alert: FDA warns consumers against the use of unapproved, dangerous tanning products containing Melanotan. PubMed / Source →
- [2] Nelson ME, et al. Melanotan II: A cause of atypical melanocytic nevi and systemic toxicity. Dermatol Online J. 2012;18(11):1. PubMed / Source →